Recent Updates
Recently added Catalysts
RCUS Positive Sentiment

Arcus Biosciences Announces New Employment Inducement Grants

Friday, October 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Arcus Biosciences has granted stock options to two new employees as part of its employment inducement program. The options total 9,150 shares at an exercise price of $23.83, aligning with the company's focus on developing innovative therapies for cancer and inflammatory diseases. This move indicates the company's commitment to attracting talent in the competitive biopharma sector.

Market Sentiment Analysis

POSITIVE FACTORS

  • Arcus Biosciences is expanding its team with new hires.
  • The granted stock options may incentivize employee performance.
  • The exercise price reflects a stable market position.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+65%
120-day peak, hindsight
Typical move
2.8%
average across 10 past catalysts
Cash runway
~17 mo
Low dilution risk
Lead asset
Etrumadenant
Phase 1 · Non-small Cell Lung Cancer

Full Press Release Details

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted 2 new employees options to purchase a total of 9,150 shares of the Company’s common stock at an exercise price per share of $23.83, which was the closing pric

Frequently Asked Questions

What did Arcus Biosciences announce?

Arcus Biosciences announced employment inducement grants for two new employees.

How many shares were granted to the new employees?

A total of 9,150 shares were granted to the new employees.

What is the exercise price for the granted shares?

The exercise price for the granted shares is $23.83 each.

What is the focus of Arcus Biosciences?

Arcus Biosciences focuses on developing therapies for cancer and inflammatory diseases.

ShareAdd on Google
Tags: RCUS Arcus Biosciences employment grants stock options biopharmaceuticals
Last updated: Oct 9, 2026

Biotech snapshot

Cash runway
$775M liquidity · $40M/mo burn
~17 mo
Low dilution risk
Lead asset
EtrumadenantPhase 1
Non-small Cell Lung Cancer →

Catalyst track record

+65%
best trade around RCUS's most recent catalyst

Peak hindsight return over a 120-day window, across 10 tracked FDA/PDUFA catalysts for RCUS.

See every catalyst's timing & PoA →